This clinical trial evaluates whether Mirtazapine is more effective than placebo in treating
agitation in people with dementia. The trial will assess the safety, clinical and cost
effectiveness of the treatment. Participants will be randomised to receive either Mirtazapine
or placebo for 12 weeks and will be followed up for up to one year, in this blinded trial.
Phase:
Phase 3
Details
Lead Sponsor:
University of Sussex
Collaborators:
Alzheimer's Society Birmingham and Solihull Mental Health NHS Foundation Trust London School of Economics and Political Science Norwich Clinical Trials Unit The Centre for Dementia Studies, Brighton and Sussex Medical School and SPFT University College, London University of Cambridge University of East Anglia University of Manchester University of Newcastle Upon-Tyne